Magnetic resonance spectroscopy in mild cognitive impairment: Systematic review and meta-analysis

Tumati, Shankar; Martens, Sander; Aleman, A.

doi:10.1016/j.neubiorev.2013.08.004

Cited by 118 publications

(85 citation statements)

References 92 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Metabolic changes in the PCG by 1 H-MRS have been previously reported in MCI and early AD, and these changes are correlated with the severity of cognitive decline [43]. Our study showed that mI was increased in the PCG in patients with AD, but not aMCI, as previously reported [13,44].…”

Section: Discussionsupporting

confidence: 88%

“…T2-weighted transverse, sagittal, and coronal gradient echo images (TR/TE = 600 ms/95 ms) were obtained to localize 1 H-MRS acquisition. The anterior cingulate voxel of interest included the anterior cingulate gyrus and the lateral prefrontal cortex [31], and the posterior cingulate voxel of interest included the posterior cingulate gyrus and the inferior precuneus [18] (Fig. 1).…”

Section: Mri and Mr Spectroscopymentioning

confidence: 99%

“…Patients with AD and MCI were reported to exhibit tissue degeneration in the posterior cingulate gyrus (PCG) [18]. However, 1 H-MRS changes in the PCG are not consistent.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

1H-MRS asymmetry changes in the anterior and posterior cingulate gyrus in patients with mild cognitive impairment and mild Alzheimer's disease

Guo

Liu

Hou

et al. 2016

Comprehensive Psychiatry

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 88%

Section: Mri and Mr Spectroscopymentioning

confidence: 99%

See 1 more Smart Citation

1H-MRS asymmetry changes in the anterior and posterior cingulate gyrus in patients with mild cognitive impairment and mild Alzheimer's disease

Guo

Liu

Hou

et al. 2016

Comprehensive Psychiatry

View full text Add to dashboard Cite

“…These metabolites might therefore be potential biomarkers of brain dysfunction in AD (Wang et al, 2015). To evaluate whether these metabolite changes are signs of early degeneration in MCI, a meta-analysis of data derived from 607 MCI patients was conducted (Tumati et al, 2013). As in AD patients, NAA measures were consistently reduced in the posterior cingulate, hippocampus and paratrigonal white matter, while Cr concentration was reduced in the hippocampus and parietal white matter.…”

Section: Magnetic Resonance Spectroscopymentioning

confidence: 99%

Magnetic resonance imaging and positron emission tomography in the diagnosis of neurodegenerative dementias

Sole¹,

Malaspina²,

A³

2016

View full text Add to dashboard Cite

SummaryNeuroimaging, both with magnetic resonance imaging (MRI) and positron emission tomography (PET), has gained a pivotal role in the diagnosis of primary neurodegenerative diseases. These two techniques are used as biomarkers of both pathology and progression of Alzheimer's disease (AD) and to differentiate AD from other neurodegenerative diseases. MRI is able to identify structural changes including patterns of atrophy characterizing neurodegenerative diseases, and to distinguish these from other causes of cognitive impairment, e.g. infarcts, space-occupying lesions and hydrocephalus. PET is widely used to identify regional patterns of glucose utilization, since distinct patterns of distribution of cerebral glucose metabolism are related to different subtypes of neurodegenerative dementia. The use of PET in mild cognitive impairment, though controversial, is deemed helpful for predicting conversion to dementia and the dementia clinical subtype. Recently, new radiopharmaceuticals for the in vivo imaging of amyloid burden have been licensed and more tracers are being developed for the assessment of tauopathies and inflammatory processes, which may underlie the onset of the amyloid cascade. At present, the cerebral amyloid burden, imaged with PET, may help to exclude the presence of AD as well as forecast its possible onset. Finally PET imaging may be particularly useful in ongoing clinical trials for the development of dementia treatments. In the near future, the use of the above methods, in accordance with specific guidelines, along with the use of effective treatments will likely lead to more timely and successful treatment of neurodegenerative dementias.

show abstract

“…45 In addition to NAA reductions in Alzheimer's disease, decreased NAA also appears in mild cognitive impairment and non-Alzheimer's dementias, 46,47 and lower NAA levels may be predictive of longitudinal cognitive decline or conversion to Alzheimer's disease. 46 While decreased NAA appears to be common in dementias, the pattern of NAA reductions, especially if combined with the patterns of other metabolites, may provide a method of differential diagnosis for dementias. 48 Huntington disease (HD) is characterized by abnormal movements and cognitive decline, and is caused by a single well-described genetic alteration, increased CAG (cytosine, adenine, and guanine trinucleotide DNA) repeat length in the Huntington gene.…”

Section: Naa In Neurodegenerative Disordersmentioning

confidence: 99%

N-Acetyl Aspartate

Edden

Harris

2016

eMagRes

View full text Add to dashboard Cite

The most prominent signal in the 1 H magnetic resonance spectrum of the human brain and spinal cord arises from N-acetyl aspartate (NAA). NAA is formed by acetylation of aspartate within the neuronal mitochondria, a reaction that helps draw glutamate back into the tricarboxylic acid cycle. Transport of NAA out of neurons is slow, leading to the build-up of a substantial concentration (∼20 mM) in the neuronal cytoplasm. NAA is broken down by deacetylation in oligodendrocytes, delivering acetyl groups for myelin formation. NAA levels are decreased in many neurological disorders, including multiple sclerosis, stroke, and Huntington disease. This decrease is loosely interpreted as indicating neuronal dysfunction. In several disorders, NAA reductions are at least partially reversible, indicating that they might arise from a reduced neuronal energy metabolism, and/or disruption of neuronal membranes, and not simply from neuronal loss.

show abstract

Magnetic resonance spectroscopy in mild cognitive impairment: Systematic review and meta-analysis

Cited by 118 publications

References 92 publications

1H-MRS asymmetry changes in the anterior and posterior cingulate gyrus in patients with mild cognitive impairment and mild Alzheimer's disease

1H-MRS asymmetry changes in the anterior and posterior cingulate gyrus in patients with mild cognitive impairment and mild Alzheimer's disease

Magnetic resonance imaging and positron emission tomography in the diagnosis of neurodegenerative dementias

N-Acetyl Aspartate

Contact Info

Product

Resources

About